Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data MACROGENICS INC files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
91.9
158
60.1
64.2
105
77.4
152
58.7
150
150
Cost of revenue
0
0
2.65
3.35
0.62
0.85
0
Gross profit
64.2
105
74.8
149
58.1
149
150
Research and development
122
147
191
195
193
215
207
167
177
147
General and administrative
29.8
32.7
40.5
46.1
42.7
63
58.9
52.2
71
39.2
Operating income
-60
-22.1
-171
-177
-131
-203
-121
-168
-111
-72.8
Interest expense
0
0
1.43
1.12
8.51
Interest income
2.3
2.4
2.3
3.4
0.8
2
1.7
4
5.6
3.4
Other non-operating income
1.51
2.52
-0.25
25.4
1.32
0.68
1.66
9.69
9.42
6.06
Pre-tax income
-120
-9.06
-66
-75.3
Income tax
0
0
0
0
0
0
0
0
0.94
-0.67
Net income
-58.5
-19.6
-171
-152
-130
-202
-120
-9.06
-67
-74.6
EBITDA
-52.4
-14.9
-162
-165
-119
-192
-110
-159
-103
-65.7
EPS, basic
-1.69
-0.54
-2.47
-3.37
-1.95
-0.15
-1.07
-1.18
EPS, diluted
-1.69
-0.54
-2.47
-3.37
-1.95
-0.15
-1.07
-1.18
Shares, basic (weighted)
34.7
36.1
40.9
48.1
52.4
59.9
61.4
61.9
62.6
63.2
Shares, diluted (weighted)
34.7
36.1
40.9
48.1
52.4
59.9
61.4
61.9
62.6
63.2
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
84.1
212
220
126
181
123
109
101
183
57.2
Receivables
2.76
13.6
29.6
12.7
23.1
10.4
56.2
10.4
4.31
0.43
Inventory
0
4.39
1.45
1.22
0
7.91
Other current assets
3.48
3.15
6.68
11.3
17
21.2
10.2
9.95
11.5
7.22
Total current assets
284
322
269
240
313
280
222
251
217
220
Property, plant and equipment
18
50
56.7
48.2
42.2
37.7
29.6
21.8
18.1
2.1
Lease right-of-use assets
20.2
19.3
16.6
27.3
23.8
24.5
21.8
Other non-current assets
1.37
1.6
6.29
24.5
23.9
1.4
1.38
1.39
1.56
0.21
Total assets
311
374
332
313
379
335
280
298
262
257
Accounts payable
4
2.45
4.01
4.31
8.03
15.5
4.9
6.44
5.01
3.26
Accrued liabilities
16.1
38.6
33.2
27.1
34.2
33.8
29
24.2
29.3
22.1
Deferred revenue
4.26
7.2
21.7
10.7
4.46
20.6
9.99
21.7
16.3
1.28
Total current liabilities
27.3
49.8
59.9
45.2
50.7
74.6
48.6
56.1
55.5
43.1
Lease liabilities
0
27.6
25.3
20.8
30.1
30.2
32.6
30.6
Other non-current liabilities
0
0
0.26
0.26
0.26
1.97
1.05
Total liabilities
42.5
74.6
89.3
81.9
82.9
95.6
138
146
146
201
Paid-in capital
561
611
733
872
1,067
1,213
1,235
1,255
1,285
1,299
Retained earnings
-293
-312
-490
-642
-772
-974
-1,094
-1,103
-1,170
-1,244
Shareholders' equity
269
299
243
231
296
240
142
153
116
55.6
Total equity
269
299
243
231
296
240
142
153
116
55.6
Total liabilities and equity
311
374
332
313
379
335
280
298
262
257
Shares outstanding
34.9
36.9
42.4
49
56.2
61.3
61.7
62.1
62.8
63.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-58.5
-19.6
-171
-152
-130
-202
-120
-9.06
-67
-74.6
Depreciation and amortization
7.61
7.23
9.16
12.3
12
11.3
11.9
9.65
7.54
7.17
Stock-based compensation
12.2
14.7
16.5
19.6
20.7
23.1
20.4
18.4
29.4
14.3
Change in receivables
-1.54
-10.9
-15.9
16.8
-10.3
12.7
-45.8
45.9
6.06
-9.06
Change in inventory
0
0
-6.42
0.06
0.23
-2.19
-7.91
Change in payables
2.23
-1.54
1.55
0.79
3.72
7.13
-10.9
1.28
-1.53
-0.28
Cash from operations
-43.7
14.4
-153
-134
-112
-144
-87
-78.2
-68.4
-81
Capital expenditures
-11.4
-29.4
-25
-4.29
-5.91
-6.2
-3.62
-1.76
-3.71
-1.91
Purchases of investments
-348
-135
-133
-264
-224
-231
-121
-240
-77.2
-208
Cash from investing
-70.2
77.9
56.6
-79.4
-7.79
-36.6
70.7
-80.1
149
-114
Stock issued
0
34.2
103
119
170
118
1.09
0.62
0
0
Cash from financing
1.85
35.3
105
120
174
123
1.66
150
0.96
69.5
Net change in cash
-112
128
8.4
-93.7
54.7
-57.7
-14.6
-7.93
81.9
-126
Free cash flow
-55.1
-15
-178
-139
-118
-150
-90.6
-80
-72.1
-83
Income taxes paid
0
0
0.94
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $3.74 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-18.7%
Operating income / revenue.
EBITDA margin
-15.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-8.0%
Net income / revenue.
FCF margin
-35.8%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-34.8%
Cash from operations / revenue.
Return on equity (ROE)
-34.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-4.2%
Net income / average total assets.
R&D / revenue
76.7%
Research and development expense / revenue.
Stock-based pay / revenue
5.9%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
1.0%
Capital expenditures / revenue.
D&A / revenue
3.2%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-0.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-0.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
7.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
0.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
0.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
7.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-52.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-26.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-28.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-1.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-2.9%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-7.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
0.9%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
3.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.96x
Current assets / current liabilities.
Quick ratio
1.27x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.05x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.88
Revenue / diluted weighted shares.
FCF per share
-$1.03
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.00
Cash from operations / diluted weighted shares.
Book value per share
$0.67
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.30x
Market cap / revenue.
P/B
5.56x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.56x
Market cap / tangible book value, when positive.
EV/Sales
0.68x
Enterprise value / revenue.
FCF yield
-27.5%
Free cash flow / market cap.
Earnings yield
-6.1%
Net income / market cap (the inverse of P/E).
What was MACROGENICS INC's revenue in fiscal 2025?
MACROGENICS INC reported revenue of $149.5M for fiscal 2025, 0.3% lower than the year before.
Was MACROGENICS INC profitable in fiscal 2025?
No. It reported a net loss of $74.6M.
How much free cash flow did MACROGENICS INC generate in fiscal 2025?
Cash from operations of $81.0M minus capital expenditures of $1.9M left free cash flow of -$83.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.